Share on LinkedInShare on LinkedIn

ARTICLE · 27 MARCH 2014

Successful Use Of Inter Partes Review To Cancel Claims Asserted In Parallel Litigation

Duane Morris LLP
Duane Morris LLP
Contributor
Explore more from Duane Morris LLP

In a trio of March 6, 2014 inter partes review (IPR) decisions, the Patent Trial and Appeal Board (PTAB) canceled patent claims related to next generation DNA sequencing technology, after Illumina, Inc. countered Columbia University’s patent infringement suit by successfully petitioning for IPR of claims in three of five of Columbia’s patents-in-suit.

United StatesIntellectual Property

In a trio of March 6, 2014 inter partes review (IPR) decisions, the Patent Trial and Appeal Board (PTAB) canceled patent claims related to next generation DNA sequencing technology, after Illumina, Inc. countered Columbia University's patent infringement suit by successfully petitioning for IPR of claims in three of five of Columbia's patents-in-suit. 

The decisions illustrate the utility of the new IPR process before the PTAB, implemented under the America Invents Act (AIA), as a parallel venue in which patent litigation defendants can challenge the patentability of claims asserted against them in litigation, more expeditiously and less costly than in court proceedings.  

The three patents, U.S. Patent Nos. 7,713,698 (the '698 patent), 7,790,869 (the '869 patent), and 8,088,575 (the '575 patent), were three of five patents-in-suit at issue in Trustees of Columbia University & Intelligent Biosystems v. Illumina, Inc., 1:12-cv-00376-UNA, pending in federal court

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from